|NASDAQ: GNFT||Healthcare / Biotechnology / France|
|4.10||0||0.00||Vol 15.10K||1Y Perf 2.50%|
|Mar 31st, 2023 15:53 DELAYED|
|- -||- -%|
|Target Price||7.67||Analyst Rating||Moderate Buy 2.00|
|Potential %||87.07||Finscreener Ranking||★★★★★ — -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 65.23|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 82.20|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||53.20||Earnings Rating||Neutral|
|Market Cap||204.24M||Earnings Date||6th Apr 2023|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Apr 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||7.68K|
|Avg. Monthly Volume||5.76K|
|Avg. Quarterly Volume||7.93K|
GENFIT S.A. (NASDAQ: GNFT) stock closed at 4.1 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 15.10K shares and market capitalization of 204.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 201 people. GENFIT S.A. CEO is Pascal Prigent.
The one-year performance of GENFIT S.A. stock is 2.5%, while year-to-date (YTD) performance is -6.58%. GNFT stock has a five-year performance of %. Its 52-week range is between 3.02 and 5.05, which gives GNFT stock a 52-week price range ratio of 53.20%
GENFIT S.A. currently has a PE ratio of 4.50, a price-to-book (PB) ratio of 1.87, a price-to-sale (PS) ratio of 22.62, a price to cashflow ratio of 2.90, a PEG ratio of 2.32, a ROA of 25.79%, a ROC of 35.95% and a ROE of 67.45%. The company’s profit margin is 53.80%, its EBITDA margin is 66.90%, and its revenue ttm is $9.21 Million , which makes it $0.18 revenue per share.
Of the last four earnings reports from GENFIT S.A., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. GENFIT S.A.’s next earnings report date is 06th Apr 2023.
The consensus rating of Wall Street analysts for GENFIT S.A. is Moderate Buy (2), with a target price of $7.67, which is +87.07% compared to the current price. The earnings rating for GENFIT S.A. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
GENFIT S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
GENFIT S.A. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.27, ATR14 : 0.18, CCI20 : -70.59, Chaikin Money Flow : -0.04, MACD : -0.08, Money Flow Index : 33.40, ROC : -0.73, RSI : 45.05, STOCH (14,3) : 36.00, STOCH RSI : 1.00, UO : 43.05, Williams %R : -64.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of GENFIT S.A. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development.
CEO: Pascal Prigent
Telephone: +33 320164000
Address: Parc Eurasante, Loos 59120, , FR
Number of employees: 201
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.